Siga Technologies, Inc.
Company Information

660 Madison Ave Ste 1700
New York, NY, 10065 United States
(212) 672-9100

Top 3 Competitors

Unlock more access to Hoover’s!

  • Build customized email lists 24/7, based on your best customer profile.
  • Learn more about the companies you want to sell to. Hoover’s has reports on 85+ million companies and 900 industries. 65,000 data points are updated each day.
  • Get real insight written by real people – exclusive research and reviews by our in-house Editorial staff.
  • We can deliver our data to your desktop, to Excel, direct to your CRM, into your custom app, or via mobile.

Call (866) 473-3932 today to get started with a FREE TRIAL!


Siga Technologies, Inc. Company Profile

SIGA Technologies is trying to put itself on the front lines of US biodefense efforts. The drug company has a number of development programs for vaccines, antivirals, and antibiotics for drug resistant infections; however, its main focus is on vaccines for bio-defense. Its smallpox vaccine Arestvyr (aka Tecovirimat, or ST-246), which is intended to both prevent and treat the disease, has received Fast Track and Orphan Drug designations from the FDA. SIGA is also developing vaccines for use against hemorrhagic fevers and other infectious diseases and biothreats. Much of its work is done through funding from the NIH and the HHS. SIGA emerged from a short stint under Chapter 11 bankruptcy protection in 2016.